Invasion-promoting membrane type-1 matrix metalloproteinase (MT1-MMP) functions in cancer cells as an oncogene and as a mediator of proteolytic events on the cell surface. To exert its functional activity, MT1-MMP requires proteolytic removal of the prodomain sequence. There are two potential furin cleavage motifs, R 89 -R-P-R-C 93 and R
Introduction
Membrane-tethered membrane type-1 matrix metalloproteinase (MT1-MMP), the prototypic member of the membrane type (MT) matrix metalloproteinase subfamily, is distinguished from soluble MMPs by a transmembrane domain and a cytoplasmic tail (CT) (Egeblad and Werb, 2002) . The transmembrane domain and the CT associate the protease with discrete regions of the plasma membrane and the intracellular milieu, respectively. Membrane type-1 matrix metalloproteinase functions in cancer cells as a mediator of proteolytic events on the cell surface (Hotary et al., 2003; Sabeh et al., 2004) , and it is directly engaged in the cleavage of cell surface receptors and the pericellular proteolysis of the extracellular matrix (ECM) components (Hernandez-Barrantes et al., 2002; Overall and Lopez-Otin, 2002) . Consistent with its invasion-promoting role, MT1-MMP is overexpressed in aggressive, metastatic neoplasms (Itoh and Seiki, 2006) .
Membrane type-1 matrix metalloproteinase is regulated at the transcriptional and post-translational levels by the coordinated mechanisms of exocytosis, endocytosis and recycling, activation of the latent MT1-MMP proenzyme by furin-like proprotein convertase (PCs), autolytic degradation, and by inhibition by tissue inhibitors of MMPs (TIMPs) (Remacle et al., 2003; Deryugina et al., 2004; Osenkowski et al., 2004; Rozanov et al., 2004; Wang et al., 2004a, b) . To exercise its functional activity, MT1-MMP requires removal of the N-terminal prodomain sequence. There are two potential furin cleavage motifs, R 89 -R-P-R-kC 93 and R 108 -R-K-R-kY 112 in the prodomain of MT1-MMP (Pei and Weiss, 1995; Yana and Weiss, 2000) . Similar motifs exist in the sequence of certain other MMPs. In the course of the secretory pathway of MT1-MMP, these motifs are targeted by furin and also by other cellular PCs (Stawowy et al., 2005) because partial MT1-MMP maturation was observed in furin-deficient cells (Yana and Weiss, 2000) . Seven furin-like PCs are known: furin/ PACE/PC1, PC2, PC1/3, PACE4, PC4, PC5/6, and PC7 (Fugere and Day, 2005) . The relative importance of PCs in the activation of MT1-MMP is not currently known.
Furin cleavages lead to the activation and to the presentation of the functionally active, commencing at Tyr 112 , mature MT1-MMP at the cell surfaces (Strongin et al., 1995; Osenkowski et al., 2004) . There is evidence that a portion of the cellular MT1-MMP pool is processed by additional PCs and also by autocatalysis directly at the cell surface (Sato et al., 1999; Yana and Weiss, 2000; Rozanov and Strongin, 2003; Deryugina et al., 2004) . Inhibition of MT1-MMP activation by furin inhibitors, including a nanomolar range a1-anti-trypsin variant Portland (PDX) inhibitor repressed motility and tumorigenicity of cancer cells (Bassi et al., 2001) .
Furin-like PCs are involved in the processing of multiple cellular proteins including neuropeptides, peptide hormones, adhesion receptors, extracellular matrix proteins and growth factors, as well as many exogenous proteins of bacterial and viral origin (Thomas, 2002; Fugere and Day, 2005) . Anthrax-protective antigen PA83 is a well-known target of furin (Seidah and Prat, 2002) . The PA83 precursor binds to the structurally similar CMG2 and TEM8 anthrax cell receptors (Scobie and Young, 2005) . Proprotein convertases cleave the RKKR 196 kS 197 site of the receptor-bound PA83. This cleavage generates cell-bound, C-terminal 63 kDa PA63. Anthrax-protective antigen-P63 oligomerizes to form a ring-shaped heptamer (Santelli et al., 2004) . A heptamer prepore binds anthrax lethal factor and edema factor and delivers them into the intracellular milieu, where they exert their toxic effect (Liu et al., 2003) .
In our study, we tested the potency of several PCs in cleaving MT1-MMP and PA83 in cell-based and in in vitro tests. Our biochemical data demonstrate that several PCs, as opposed to furin alone, can activate MT1-MMP by cleaving the R 108 -R-K-R-kY 112 site while the R 89 -R-P-R-C 93 site of the MT1-MMP proenzyme is inaccessible to PCs. We also determined the presence of the specialized cellular machinery that specifically eliminates the latent proenzyme and, simultaneously, extends the presentation of the MT1-MMP enzyme on the cell surface thus continually supporting the potency of pericellular proteolysis.
Results
Processing of the peptides that span the membrane type-1 matrix metalloproteinase furin cleavage motifs The furin cleavage of MT1-MMP at the R 89 -R-P-R-C 93 and R
108
-R-K-R-Y 112 motifs (Yana and Weiss, 2000) should, in theory, generate the proteinase species commencing at Cys 93 and Tyr
112
, respectively. According to the N-terminal sequencing of cellular MT1-MMP, the Tyr 112 -species represents the fully mature enzyme (Strongin et al., 1995 Figure 1 Schematic representation of the domain structure of membrane type-1 matrix metalloproteinase (MT1-MMP). S, PRO, CAT, H, PEX, TM and CT: the signal peptide, the prodomain, the catalytic domain, the hinge region, the hemopexin domain, the transmembrane domain and the cytoplasmic tail, respectively. DCT, MT1-MMP mutant lacking amino acids 563-582 of the CT. R 89 -R-P-R-C 93 and R 108 -R-K-R-Y 112 are the potential furin cleavage sites in the MT1-MMP prodomain. R89A, ARAA and R89A/ARAA are mutants in which the first, the second and both furin sites were inactivated by mutations. The 42-45 kDa membrane-tethered species lack the catalytic domain of MT1-MMP. As the R 89 -R-P-R-C 93 sequence is in the immediate proximity of the active site and because it is shielded by the prodomain in the structure of the MT1-MMP proenzyme, it cannot be accessed by furin and, therefore, a C 93 -intermediate was not detected in our studies. (Kridel et al., 2002) was readily cleaved by the protease which generated the SGRIGF cleavage fragment. GM6001, a potent inhibitor of MT1-MMP (k i ¼ 0.5 nM) (Ratnikov et al., 2000) , blocked the MT1-MMP cleavage. PC5/6 also efficiently cleaved both Processing of cellular membrane type-1 matrix metalloproteinase and activation of MMP-2 To determine the role of PCs in the activation of MT1-MMP and in the generation of its multiple cell surfaceassociated forms, we used glioma U251 cells stably expressing the wild type and the mutant MT1-MMP including the internalization-deficient DCT mutant , the R89A mutant with the inactivated R 89 -R-P-R-C 93 cleavage site, the ARAA mutant with the inactivated R 108 -R-K-R-kY 112 cleavage site and the R89A/ARAA mutant with both R 89 -R-P-R-C 93 and R 108 -R-K-R-kY 112 inactivated sites. Inactivation of the furin sites by the ARAA and the R89A mutations were convincingly established by earlier works (Yana and Weiss, 2000; Cao et al., 2005) . Glioma cells expressing these constructs were lysed and the lysates were analysed by Western blotting with an MT1-MMP antibody. Gelatin zymography was used to determine the ability of the constructs to activate MMP-2 which is naturally produced by glioma cells (Deryugina et al., 1997) . The efficiency of MMP-2 activation is proportional to the functional activity of cellular MT1-MMP. Our data suggest that MT1-MMP was represented by the putative proenzyme, the intermediate and the mature enzyme (the upper, the middle and the bottom bands, respectively) ( Figure 3a ) and that incomplete glycosylation, rather than the proteolytic processing at the R , Thr 300 and Ser 301 sites in the proline-rich hinge region (Wu et al., 2004) . We used BGN (a synthetic N-acetylgalactosamine analogue and a competitive inhibitor of b1-3galactosyltransferases) (Kuan et al., 1989) to inhibit the glycosylation of MT1-MMP. For these purposes, WT and WT/PDX cells were initially co-incubated with BGN and then with both BGN and GM6001. Figure 3b shows that deglycosylation decreased the apparent molecular weight of both the MT1-MMP proenzyme and enzyme forms and that the intermediate likely represented the incompletely glycosylated MT1-MMP proenzyme. As expected, tunicamycin (an inhibitor of N-glycosylation) had no effect on MT1-MMP (not shown). The treatment of the MT1-MMP samples with peptide-Nglycosidase F also did not affect the mobility of the protease forms (not shown). Figure 3a shows no activation of MMP-2 in mock cells. In turn, WT cells efficiently activated MMP-2. Consistent with the earlier observation (Jiang et al., 2001; Wang et al., 2004b) , the DCT construct was highly potent in activating MMP-2. The R89A mutant exhibited high levels of MMP-2 activation. In contrast, the ARAA mutant with the functional R 89 -R-P-R-C 93 site and the R89A/ARAA double mutant were each predominantly observed as the proenzymes and they did not activate MMP-2 efficiently. The presence of the limited amounts of the mature enzyme in the cells expressing the ARAA and R89A/ARAA mutants is easily explained by the contribution of naturally expressed MT1-MMP and also by the processing of MT1-MMP by plasmin (Okumura et al., 1997) , significant quantities of which are produced by U251 cells (Sitrin et al., 1990) .
The uptake rate of membrane type-1 matrix metalloproteinase To identify the cell surface-associated species of MT1-MMP and, then, to determine their internalization rate, we used a cell-surface biotinylation procedure with membrane-impermeable, cleavable, EZ-Link NHS-SSbiotin. Biotinylation of WT, WT/PDX, ARAA, R89A, R89A/ARAA and DCT cells was followed by incubation of the cells at 371C to initiate protein uptake. Cells were next transferred on ice to arrest protein trafficking and then treated with MESNA to release the biotin moiety from the residual cell surface MT1-MMP. The biotin-labeled internalized MT1-MMP was protected from MESNA. The labeled MT1-MMP pool was captured on streptavidin beads and then identified by Western blotting. Cell surface-associated MT1-MMP was represented by only the mature enzyme in WT, DCT and R89A cells (Figure 4) . In WT/PDX cells, both the mature enzyme and the proenzyme of MT1-MMP were detected. In agreement with Figure 3 , both ARAA and R89A/ ARAA mutants predominantly expressed the proenzyme and, in addition, low concentrations of the mature enzyme.
Membrane type-1 matrix metalloproteinase uptake studies demonstrated the higher internalization rate of the proenzyme when compared to the enzyme. The difference in the uptake rate of the enzyme and the proenzyme was especially evident in WT/PDX cells (Figure 4) . Thus, after a 15-min uptake, the bulk of the biotin-labeled proenzyme had been protected from The uptake of MT1-MMP by the cells. WT, WT/PDX, ARAA, R89A, R89A/ARAA and DCT cells were incubated for 16 h with GM6001 and then surface biotinylated with cleavable EZ-Link NHS-SS biotin. The cells were next incubated for 15 min at 371C to allow cell surface-associated MT1-MMP to be internalized. Biotin-labeled MT1-MMP was captured on streptavidin beads and examined by Western blotting. Where indicated, MESNA was used to release a biotin moiety from the cell surfaceassociated proteins. The gels were scanned and the images were digitized. The density of the individual P and E MT1-MMP bands was expressed as a percentage compared to the total MT1-MMP (P þ E ¼ 100). One representative experiment is shown. Multiple additional experiments generated similar results. P and E: the proenzyme and the enzyme of MT1-MMP, respectively. Abbreviations: CT, cytoplasmic tail; MESNA, 2-mercaptoethane sulfonic acid; MT1-MMP, membrane type-1 matrix metalloproteinase; PDX, a 1 -anti-trypsin Portland; WT, wild type.
MESNA. To quantitatively assess the results, the gels were scanned and the images were digitized. The density of the P and E bands was expressed as a percentage relative to the total MT1-MMP (P þ E ¼ 100). The P:E ratio was equaled to 60:40 in the untreated WT/PDX cells, whereas after the MESNA treatment this ratio was 40:60. These data indicated that the uptake rate of the inert MT1-MMP proenzyme noticeably exceeded that of the active enzyme. The data obtained in ARAA and R89A/ARAA cells support this conclusion (Figure 4) . Consistent with our earlier findings , an especially low uptake rate was an attribute of the DCT construct. Similar results were obtained in the 30-min uptake experiments (not shown).
Processing of membrane type-1 matrix metalloproteinase and anthrax-protective antigen-83 by proprotein convertase Proteolytic processing and activation of MT1-MMP by furin and related PCs occurs predominantly intracellularly (Thomas, 2002) . In agreement, intracellularly expressed PDX significantly, albeit incompletely, inhibited the activation of MT1-MMP (Figures 4 and 5) . These results suggest that PC7, which is less sensitive than furin to PDX (Jean et al., 1998) , might be involved in the processing of MT1-MMP in WT/PDX cells.
To test this hypothesis, we determined the efficiency of the processing of anthrax PA83 in glioma cells. It is well established that, following its binding with the cell receptor, furin cleavage of PA83 occurs directly at the cell membrane rather than in intracellularly (Bradley and Young, 2003) . In our tests, cells were allowed to bind and to process PA83. The amounts of cellassociated PA83 and PA63 were determined by Western blotting. The conversion of PA83 was observed in WT cells but not in WT/PDX cells suggesting that the furin activity was fully blocked in WT/PDX cells. Dec-RVKR-cmk by inhibiting cell surface-associated furin blocked the PA83 conversion in WT cells. GM6001 had no effect on either the binding or the processing of PA83 ( Figure 5 ).
In contrast with PA83, an incomplete inhibition of the MT1-MMP processing was observed in WT/PDX cells. Dec-RVKR-cmk also caused an incomplete inhibition of MT1-MMP processing. These results are not surprising because this peptide is more efficient in accessing the cell surface protease than the intracellular milieu. GM6001 inhibited the autolytic degradation of MT1-MMP and, as a result, increased the concentrations of the mature enzyme in both WT and WT/PDX cells. In contrast to GM6001, dec-RVKR-cmk caused inhibition of MT1-MMP processing in WT cells. In WT/ PDX cells, the effects of dec-RVKR-cmk were less visible. Taken together, these results suggest that furin was fully inhibited in WT/PDX cells and that furin was the main enzyme involved in the processing of PA83 in glioma cells while an additional PC (most probably, PC7) contributed to the activation of MT1-MMP.
To confirm that PA83 and MT1-MMP are sensitive to the individual PCs, we used in vitro cleavage tests employing purified PCs. PA83 and the soluble MT1-MMP proenzyme were each incubated with the purified PCs and then analysed by Western blotting. Figure 5 demonstrates that furin, PC5/6, PC7 and PACE4 were capable of cleaving PA83 and MT1-MMP, albeit with different efficiencies. Among these PCs, furin and PC5/6 were most efficient. These data demonstrate that distinct PCs can substitute for furin in the processing of MT1-MMP and anthrax PA83.
Furin, PC5/6 and PC7 are expressed in glioma U251 cells To determine gene expression of PCs in glioma U251 cells we used RT-PCR. The RT-PCR products of a predicted size were generated for PC5/6, PC7 and furin. Sequencing of the PCR products confirmed their authenticity. Figure 5c shows the high, similar, expression levels of PC5/6, PC7 and furin in glioma cells. The expression of other PCs was very low, if any, in glioma cells. These results support the role of PC7 (a PC that is resistant to PDX) (Jean et al., 1998) in the activation of MT1-MMP that was observed in WT/PDX cells.
Discussion
Membrane type-1 matrix metalloproteinase has been implicated in the pericellular proteolysis in events ranging from normal development to malignant progression (Hotary et al., 2003; Chun et al., 2004; Holmbeck et al., 2004) . MT1-MMP requires proteolytic activation and the removal of the N-terminal prodomain sequence in order to be converted into the catalytically active species (Murphy et al., 1999) . Activation by PCs occurs in the secretory pathway of the de novo synthesized MT1-MMP and this process is tightly linked to the presentation and, consequently, to the activity of cellular MT1-MMP (Seidah and Prat, 2002; Osenkowski et al., 2004) . Following activation and transport to the cell surface, MT1-MMP assumes control of cell locomotion, angiogenesis, and tumorigenesis (Hotary et al., 2003; Sabeh et al., 2004) . Autolytic activation and the follow-on degradation add further complexity to the regulation of MT1-MMP Osenkowski et al., 2004; Toth et al., 2005) . A precise understanding of these events is vital for the design of potent means to control the tumorigenicity of MT1-MMP.
There are two potential furin cleavage motifs (R GVPD cysteine-switch motif in the sequence of MT1-MMP. Taken together, our in vitro and cellbased tests suggested that PC5/6, PACA4 and, especially PC7, can potentially substitute for furin in the activation of MT1-MMP. We determined that the putative R 89 -R-P-R-C 93 site was resistant to PACE4 and PC7, while both PCs could target the R . In contrast, both the R 89 -R-P-R-C 93 and R
108
-R-K-R-Y 112 sequences were sensitive to furin. PC5/6 was also capable of cleaving both peptides and activating MT1-MMP and anthrax PA83. The cleavage sites of PC5/6, however, were not identical to those of other PCs.
It appears that MT1-MMP commencing at Cys 93 is never generated in the cells. Our results agree well with the structural data, which suggest that the R 89 -R-P-R-C 93 site is, in fact, inaccessible to furin in the MT1-MMP proenzyme. The R 89 -R-P-R-C 93 sequence includes the active site Zn 2 þ -binding Cys 93 and this region is shielded from the external proteases by the prodomain sequence (Fernandez-Catalan et al., 1998; Morgunova et al., 1999 Morgunova et al., , 2002 Gomis-Ruth, 2003) .
Our results also suggest that autolytic activation of overexpressed recombinant MT1-MMP that was observed earlier in yeasts and in lung carcinoma LoVo cells (Rozanov and Strongin, 2003; Deryugina et al., 2004) involves the cleavages that are proximal to the R 108 -R-K-R-Y 112 site. Our experiments also demonstrated a functional link between the activation and the internalization of MT1-MMP. According to our data, the uptake rate of the inert MT1-MMP proenzyme exceeded that of the active enzyme. Our data confirm and extend the previous observations of other laboratories and suggest an important role of furin and related PC5 and PC7 in regulating MT1-MMP's functionality (Yana and Weiss, 2000; Mazzone et al., 2004; Stawowy et al., 2005) . We conclude that furin-related PCs are the essential components of the specialized cellular machinery that extends the presentation of the MT1-MMP enzyme on the cell surface and supports the potency of pericellular proteolysis.
Materials and methods

Antibodies and general reagents
Reagents were purchased from Sigma (St Louis, MO, USA) unless indicated otherwise. The hydroxamate inhibitor GM6001, the soluble pro-MT1-MMP, the Ab815 rabbit antibody to the MT1-MMP hinge domain and a TMB/M substrate were from Chemicon (Temecula, CA, USA). Decanoyl-Arg-Val-Lys-Arg-chloromethylketone (dec-RVKRcmk; an inhibitor of furin) was obtained from Bachem Bioscience (King of Prussia, PA). The protease inhibitor cocktail set III, and the fluorescence peptide substrate pyroGlu-Arg-Thr-Lys-Arg-methyl-coumaryl-7-amide (pERTKRamc) were obtained from Calbiochem (San Diego, CA, USA). Sulfosuccinimidyl-2-(biotinamido) ethyl-1,3-dithiopropionate (EZ-Link sulfo-NHS-SS-biotin) and sulfosuccinimidyl-6-(biotinamido) hexanoate [EZ-Link sulfo-NHS-Long Chain(LC)-biotin] were from Pierce (Rockford, IL, USA). Recombinant human furin, PC5/6 and PC7, and rat PACE4 were prepared in the S2 Drosophilia expression system (Invitrogen, Carlsbad, CA, USA) and purified to homogeneity (Fugere et al., 2002) . Anthrax PA83 and PA63 were purchased from List Biological Laboratories (Campbell, CA, USA).
Cell lines
In our studies, we used human U251 glioma cells stably expressing the wild-type MT1-MMP (WT cells) and the MT1-MMP mutant constructs including the R89A mutant with the inactivated R 89 -R-P-R-kC 93 furin cleavage site (R89A cells), the ARAA mutant with the inactivated R 108 -R-K-R-kY 112 cleavage site (ARAA cells), the R89A/ARAA mutant with both furin cleavage sites inactivated (R89A/ARAA cells), and the tailless mutant with the truncated sequence of the CT (DCT cells). As a control, we used U251 cells stably transfected with the two original pcDNA3.1-zeo and-neo plasmids (mock cells). In addition, we used WT cells that stably co-expressed MT1-MMP with PDX (WT/PDX cells). The WT/PDX cells were initially transfected with MT1-MMP and then with PDX. All of these cell lines were constructed and characterized earlier (Rozanov et al., 2001 (Rozanov et al., , 2002 Deryugina et al., 2004) .
Cells were maintained in DMEM supplemented with 10% fetal bovine serum and gentamicin (10 mg/ml). Where indicated, cells were co-incubated for 16 h with GM6001 (25 mM) and dec-RVKR-cmk (50 mM) to inactivate MT1-MMP and furin, respectively.
Deglycosylation of membrane type-1 matrix metalloproteinase To inhibit O-glycosylation, cells were co-incubated for 24 h with benzyl 2-acetamido-2-deoxy-a-D-galactopyranoside (BGN; 2 mM) alone and then for an additional 24 h with both BGN and GM6001 (25 mM). The cells were then lysed in an RIPA buffer (20 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 1% deoxycholate, 1% IGEPAL, pH 7.4) containing a protease inhibitor cocktail set III, 1 mM phenylmethylsulfonylfluoride (PMSF) and 10 mM EDTA. To detect MT1-MMP, the lysate aliquots (30 mg of total protein each) were analysed by Western blotting with the Ab815 antibody followed by horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody and a TMB/M substrate.
Biotinylation and mercaptoethane sulfonic acid treatment Cells grown to an 80-90% confluence were washed with an icecold Soerensen Buffer (SBS), pH 7.8, containing 14.7 mM KH 2 PO 4 , 2mM Na 2 HPO 4 and 120 mM sorbitol, and then incubated for 10 min in ice-cold SBS. Cell surface-associated MT1-MMP was biotinylated by incubating cells for 20 min on ice in SBS containing 0.3 mg/ml EZ-Link NHS-SS-biotin. Excess biotin was removed by washing cells in ice-cold SBS. Residual biotin was quenched by incubating cells for 10 min in SBS containing 100 mM glycine. Cells were then washed in SBS and incubated for 15-30 min at 371C in L-15 medium with a 1% insulin-transferrin-selenium supplement to allow the internalization of biotin-labeled MT1-MMP. To liberate the residual cell-surface biotin, cells were incubated for 25 min in ice-cold SBS containing 150 mM MESNA. After washing with SBS, cells were lysed in an RIPA buffer containing a protease inhibitor cocktail set III, 1 mM PMSF and 10 mM EDTA. MT1-MMP was precipitated from cell lysates using streptavidin-agarose beads and analysed by Western blotting with the MT1-MMP antibody followed by goat anti-rabbit IgG-HRP. Gelatin zymography of medium aliquots to detect the 68 kDa proenzyme, the 64 kDa activation intermediate and the 62 kDa enzyme of MMP-2 was performed as described in our earlier publications (Deryugina et al., 1997) .
In vitro cleavage of PA83 and membrane type-1 matrix metalloproteinase PA83 and PA63 were each labeled with EZ-Link sulfo-NHC-LC-biotin (at a 1:20 protein-biotin molar ratio) for 30 min at ambient temperature. MT1-MMP and biotin-labeled PA83 (500 ng each) were co-incubated for 2 h at 371C with furin, PC5/6, PC7 and PACE4 (one unit of activity each). One unit of the PC activity was equal to the amount of the enzyme that was required to cleave 1 pmole/min of the pERTKR-amc fluorescent peptide substrate at 371C. Where indicated, dec-RVKR-cmk (5 mM) was added to the reactions to inhibit PCs. The buffer for furin cleavage reactions was 100 mM HEPES, pH 7.5, containing 1 mM CaCl 2 and 1 mM b-mercaptoethanol. The buffer for PACE4 and PC7 was 20 mM Tris-HCl, pH 6.5, supplemented with 1 mM CaCl 2 . The cleavage was stopped by adding a 5 Â SDS sample buffer. The digests were analysed by Western Blotting with ExtrAvidin-HRP (for detecting PA83/ PA63) and with the MT1-MMP antibody followed by goat anti-rabbit IgG-HRP.
Binding and processing of anthrax-protective antigen-83 by cultured cells WT and WT/PDX cells (3 Â 10 5 cells each) were incubated for 2 h at 371C in serum-free DMEM supplemented with biotinlabeled PA83 (1 mg/ml). Where indicated, GM6001 (25 mM) and dec-RVKR-cmk (50 mM) were added to the cells. After incubation, cells were washed and lysed in the RIPA buffer containing a protease inhibitor cocktail set III, 1 mM PMSF and 10 mM EDTA. To determine the concentrations of cellassociated PA83 and PA63, the samples were analysed by Western blotting with ExtrAvidin-HRP and a TBM/M substrate.
Cleavage of synthetic peptides
The peptides A 87 MRRPRCGVPD (1257 Da) and A 105 NVRRKRYAIQ (1375 Da) that span the furin cleavage sites in the prodomain of MT1-MMP were synthesized by GenScript (San Diego, CA, USA). The peptide (1.5 mg each) were incubated for 2 h at 371C in the cleavage buffer supplemented with furin, PC5/6, PACE4 and PC7 (one unit of activity each). Where indicated, MT1-MMP (400 ng; a 1:180 enzyme-substrate ratio) was added to the reactions instead of PCs. The buffer for the MT1-MMP cleavage reactions was 50 mM HEPES, pH 6.8, supplemented with 10 mM CaCl 2 , 0.5 mM MgCl 2 and 50 mM ZnCl 2 . The mass of the intact peptides and the cleavage products was determined by Mass spectrometry. The peptide SGRIGFLRTA (1077 Da), which is highly sensitive to MT1-MMP (Kridel et al., 2002) , was used as a control. The predicted mass of the SGRIGF, A 87 MRRPR and A 105 NVRRKR cleavage products is 635.71 Da, 785.96 Da and 899.05 Da, respectively. Where indicated, dec-RVKR-cmk (5 mM) and GM6001 (2.5 mM) were added to the reactions to inhibit PCs and MT1-MMP, respectively.
Reverse transcription-polymerase chain reaction amplification of proprotein convertases in glioma U251 cells Reverse transcription-polymerase chain reaction amplification primers were chosen from unique sequences of human PC1/3, PC2, PACE4, PC5/6, PC7 and furin. The sequence of the primers is shown in Cheng et al. (1997) . RNA was extracted from glioma U251 cells by a Trizol reagent (Invitrogen). Superscript II reverse transcriptase (Roche Molecular Systems, Pleasanton, CA, USA) was used in the reactions. Taq DNA polymerase (Roche) was used in the PCR reactions. Linearity of the PCR products for PCs was obtained between 25-35 amplification cycles. Thus, for quantification of RT-PCR products, 30 cycles were used for PCs and furin. After PCR, a sample aliquot was electrophoresed in a 1.5% agarose gel containing ethidium bromide. The expected size of the PCR products of PC1/3, PC2, PACE4, PC5/6, PC7 and furin was 457, 261, 456, 510, 471 and 399 bp, respectively. The PCR products were sequenced to confirm their authenticity.
Abbreviations BGN, benzyl 2-acetamido-2-deoxy-a-D-galactopyranoside; CT, cytoplasmic tail; dec-RVKR-cmk, decanoyl-Arg-ValLys-Arg-chloromethylketone; HRP, horseradish peroxidase; MESNA, 2-mercaptoethane sulfonic acid; MT1-MMP, membrane type-1 matrix metalloproteinase; PA83 and PA63, anthrax-protective antigen-83 and -63, respectively; PC, proprotein convertase; PDX, a 1 -anti-trypsin Portland; pERTKR-amc, pyro-Glu-Arg-Thr-Lys-Arg-methyl-coumaryl-7-amide; PMSF, phenylmethylsulfonylfluoride; RT-PCR, reverse transcription-polymerase chain reaction amplification; WT, wild-type.
